simulation page

Product Overview

This case examines the July 2016 decision by Israeli pharmaceutical Teva Pharmaceuticals Industries Limited (Teva) to raise USD19.5 billion in cash through a multicurrency bond offering to finance an acquisition that would firmly solidify Teva’s position as the largest generic pharmaceuticals manufacturer in the world. In light of a pending acquisition of Actavis,

Learning Objectives

•Learn to identify a firm’s competitive position and value proposition in its market •Help students recognize that capabilities emerge from the alignment of systems, processes, and people both internally and externally. •Develop the skill to analyze facts and data to make recommendations on future strategy. •Understand that capabilities provide sustainable competitive advantage to the extent they are unique, hard to imitate, and sustainable. •Examine factors and strategic considerations for scaling an organization globally.